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Introduction {#sec1}
============

Human pluripotent stem cells (hPSCs) represent a unique tool to study early cell fate decisions as they can be grown indefinitely *in vitro* while maintaining the capacity to differentiate into the three germ layers: endoderm, mesoderm, and neuroectoderm ([@bib31]). The role of the cell cycle machinery in this process has recently been explored and various studies have established that specification of the germ layers is regulated by cell cycle regulators ([@bib22], [@bib23], [@bib28], [@bib29]); however, extensive biochemical and molecular analyses of these interplays have been hindered by the difficulty of successfully synchronizing a large quantity of stem cells in the different phases of the cell cycle.

Of particular interest, the fluorescence ubiquitination cell cycle indicator (FUCCI) system ([@bib27]) can be used in hPSCs for live imaging and for sorting cells in different phases of their cell cycle for transcriptomic analyses ([@bib23], [@bib28]). Nonetheless, the FUCCI system presents several limitations. Sorting large amounts of cells is challenging, as it compromises viability and decreases efficacy of differentiation, thereby precluding precise biochemical analyses. In addition, cells in S and G2/M phases cannot be separated using the FUCCI system, limiting studies investigating mechanisms occurring specifically in these phases of the cell cycle. Finally, the FUCCI system does not distinguish between cells in early G1 or quiescence cells. These limitations highlight the need for the development of alternative tools and complementary approaches to synchronize the cell cycle in hPSCs.

Traditionally, somatic cells have been successfully synchronized using small molecules inhibiting cell cycle progression. Those include G1 phase inhibitors, such as lovastatin and mimosine. Lovastatin is a 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) inhibitor and results in G1 cell cycle arrest by inducing CDKIs, such as p21 and p27 ([@bib12], [@bib16], [@bib25]). Mimosine is an iron chelator that blocks initiation and elongation of replication forks ([@bib8], [@bib14], [@bib17], [@bib33]), resulting in accumulation of cells in the late G1 phase. Inhibitors of G1/S phase transition are also commonly used, such as aphidicolin and thymidine. Thymidine causes inhibition of DNA replication ([@bib30]), while aphidicolin blocks DNA polymerase-α, thereby arresting cells at the G1/S phase boundary ([@bib13], [@bib24]). Furthermore, hydroxyurea results in accumulation of cells in the S phase by inhibiting ribonucleotide reductase and dNTP production ([@bib1], [@bib4]). Last, G2/M phase inhibitors include colcemid and nocodazole. Both inhibit microtubule polymerization and were shown to arrest somatic and embryonic stem cells in G2/M ([@bib3], [@bib11]). Importantly, previous studies have used some of these molecules to synchronize hPSCs ([@bib6], [@bib10], [@bib11], [@bib35]); however, these methods were often associated with cell death and accumulation of genomic anomalies while their impact on pluripotency and self-renewal remains to be comprehensively analyzed. In this study, we optimized and characterized the use of these inhibitors to synchronize the cell cycle of hPSCs. We observed that a low dose of nocodazole successfully enriches for hPSCs in G2/M without affecting pluripotency and genetic stability. In addition, nocodazole-treated hPSCs can successfully differentiate into the three germ layers and can generate functional cell types, including cardiomyocytes, smooth muscle cells, chondrocytes, and hepatocytes. Finally, we used this approach to differentiate hPSCs into endoderm while being synchronized for their cell cycle, thereby creating an approach to study mechanisms occurring during cell cycle progression upon differentiation. Accordingly, we performed single-cell RNA-sequencing (RNA-seq) analysis during definitive endoderm formation using hPSCs synchronized by nocodazole treatment, and showed that cell cycle synchronization does not affect gene expression or efficiency of differentiation. Taken together, our results demonstrate that cell cycle synchronization by nocodazole does not affect the fundamental characteristics of hPSCs while providing a valuable tool to study the interplays between cell cycle and differentiation.

Results {#sec2}
=======

Nocodazole Is the Only Small Molecule that Can Efficiently Synchronize the Cell Cycle of Human Embryonic Stem Cells {#sec2.1}
-------------------------------------------------------------------------------------------------------------------

In order to identify small molecules that successfully synchronize human embryonic stem cells (hESCs), we tested a panel of inhibitors commonly used with somatic cell types ([Figures 1](#fig1){ref-type="fig"}A and 1B). Conventional doses used in somatic cells resulted in cell death within 6 to 20 hr of treatment (data not shown), indicating that the concentrations of cell cycle inhibitors tolerated by stem cells is different from the threshold tolerated by somatic cells. For this reason, we performed extensive tests to identify the optimal conditions that would block cell cycle progression without toxicity. This screen revealed that only doses up to ten times lower than the ones conventionally used were tolerated by hPSCs. At lower doses, G1 and S phase inhibitors did not affect hPSCs colony morphology with the exception of mimosine, which systematically induced cell death ([Figure 1](#fig1){ref-type="fig"}C). Concerning the G2/M inhibitors, most hPSCs were arrested in mitosis and acquired a specific round morphology and increased size ([Figure 1](#fig1){ref-type="fig"}C). Having solved the toxicity problem, we then aimed to identify the optimal timing of treatment. For that, we incubated hESCs with each inhibitor for 16 or 24 hr and subsequently performed cell cycle profile analysis using EdU incorporation. Most inhibitors enriched hPSCs in specific cell cycle phases and few differences were observed between the two time-points ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Thus, we decided to apply inhibitors for 16 hr in all subsequent experiments. Concerning the G1 phase inhibitors, lovastatin increased by only 9% the fraction of cells in G1 when compared with DMSO-treated cells. Mimosine treatment resulted in a higher enrichment, with 70% of the cells being in G1 phase; however, most of the cells were dead after 16 hr of treatment ([Figure 1](#fig1){ref-type="fig"}C). S phase inhibitors gave different results, with thymidine consistently producing a single population of cells without clear cell cycle phase identity ([Figure S1](#mmc1){ref-type="supplementary-material"}A). This observation can be explained by the fact that cells are blocked at the G1/S transition. Aphidicolin sometimes resulted in the same profile as thymidine, whereas in other cases cells were enriched in the S phase (70%) ([Figure S1](#mmc1){ref-type="supplementary-material"}A), suggesting that the synchronization during G1/S transition is not reliable. Hydroxyurea successfully enriched hPSCs in S phase (70%) while nocodazole treatment successfully enriched hESCs in G2/M (\>80%). Colcemid treatment proved less efficient with only around 40% of cells being found in G2/M and was thus excluded from further studies ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Based on these encouraging results, we decided to further refine the optimal dose for each inhibitor. Higher dose systematically improved cell cycle synchronization. However, lovastatin and mimosine treatment still failed to generate homogeneous populations of hESCs blocked in G1 ([Figure S1](#mmc1){ref-type="supplementary-material"}B) and thus were excluded from further studies. Concerning S phase inhibitors, synchronization was very efficient (\>70%) ([Figure S1](#mmc1){ref-type="supplementary-material"}B); however, release from these inhibitors systematically resulted in a heterogeneous population. Indeed, removal of thymidine and aphidicolin allowed the cells to progress in S phase ([Figures 1](#fig1){ref-type="fig"}D, 1E, [S1](#mmc1){ref-type="supplementary-material"}C, and S1D). However, hESCs became asynchronous 12 hr after release, with 50% of the cells in the G2/M phase upon release from thymidine inhibition, whereas in the case of aphidicolin, cell cycle profile was similar to DMSO-treated cells ([Figures 1](#fig1){ref-type="fig"}D, 1E, [S1](#mmc1){ref-type="supplementary-material"}C, and S1D). In the case of hydroxyurea, the percentage of cells in the S phase remained constant throughout the time course after release from inhibition, indicating that the cells remain arrested in the S phase ([Figures 1](#fig1){ref-type="fig"}F and [S1](#mmc1){ref-type="supplementary-material"}E). Finally, nocodazole treatment resulted in the most efficient synchronization (\>90% of cells in G2/M) while the cells remained synchronous after release and moved homogeneously through the cell cycle for 24 hr. More precisely, the cells progressed into G1 2 hours following removal of nocodazole, with 70% of the cells in G1 at 4 hr and 80% of the cells in S phase after 12 hr ([Figures 1](#fig1){ref-type="fig"}G, [S1](#mmc1){ref-type="supplementary-material"}F, [2](#fig2){ref-type="fig"}A, and 2B). Importantly, this synchronization lasted for one cell cycle, after which the cells acquired a heterogeneous cycle profile, thereby suggesting that different hESCs could progress through cell cycle at a different speed ([Figures 1](#fig1){ref-type="fig"}G, [S1](#mmc1){ref-type="supplementary-material"}F, [2](#fig2){ref-type="fig"}A and 2B). These observations were confirmed by examining the expression of cyclins D1, D2, and D3, which were specifically enriched in late G1. Accordingly, low levels of cyclin D proteins were observed at time zero after removal of nocodazole when cells were in the G2/M, while their levels steadily increased reaching a peak 4 hr after release when most hESCs are in G1 ([Figure 2](#fig2){ref-type="fig"}C). These results demonstrate that nocodazole can be applied to generate a near homogeneous population of hESCs synchronized for their cell cycle without altering cell cycle mechanisms such as periodicity of cell cycle regulators.Figure 1Nocodazole Is the Most Efficient Small-Molecule Inhibitor to Synchronize the Cell Cycle in hPSCs(A) Schematic showing the cell cycle phase inhibited by small molecules.(B) Schematic overview of the experimental setup to determine the efficiency of each small molecule for synchronizing the cell cycle of hESCs.(C) Brightfield images of colony morphology of H9 hESCs after 16 hr of treatment with the different small molecule cell cycle inhibitors. Scale bars, 400 μm.(D--G) Cell cycle profile of H9 hESCs following treatment and removal of cell cycle inhibitors thymidine (D), aphidicolin (E), hydroxyurea (F), and nocodazole (G) through a time course of 24 hr.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.Figure 2Cell Cycle Synchronization Is Partially Maintained after Release from Nocodazole Inhibition(A) Cell cycle profile of H9 hESCs following release from nocodazole inhibition. Samples were analyzed through a time course of 24 hr.(B) Bar graph summarizing the flow cytometry cell cycle profile analysis of H9 hESCs. Error bars represent ±SEM of five independent experiments.(C) Western blot for cyclin D1, cyclin D2, and cyclin D3 proteins in H9 hESCs through a time course of 24 hr following nocodazole release.

hESCs Remain Pluripotent and Karyotypically Normal following Nocodazole Treatment {#sec2.2}
---------------------------------------------------------------------------------

Importantly, we observed that nocodazole treatment affects morphology of hESC colonies, with the majority of cells increasing in size and losing their epithelial characteristics ([Figure 3](#fig3){ref-type="fig"}A). These changes are likely to be associated with the arrest of cell cycle progression in mitosis. Despite the morphological changes observed, treatment with nocodazole did not cause increased apoptosis and cell death, as assessed by Annexin V and propidium iodide analysis ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Furthermore, nocodazole inhibits microtubule polymerization and this mechanism could result in abnormal chromosome segregation and thus flagrant genetic anomalies. Thus, we decided to investigate whether nocodazole could affect pluripotency and genomic integrity of hESCs. Of note, 12 hr after nocodazole release, the cells recovered and acquired a normal morphology, which was maintained over a prolonged period ([Figure 3](#fig3){ref-type="fig"}A). In agreement with these observations, gene expression, flow cytometry, and immunostaining analysis showed that expression of *OCT4*, *NANOG*, and *SOX2* were similar in DMSO- and nocodazole-treated cells ([Figures 3](#fig3){ref-type="fig"}B--3E). Moreover, absence of markers specific for the three embryonic lineages (*T, EOMES, SOX17, SOX1*, and *PAX6*) confirmed that nocodazole treatment does not cause background differentiation in hESC cultures. These results were confirmed in cells 24 hr after nocodazole release ([Figure 3](#fig3){ref-type="fig"}B), as well as passage 2, passage 3, and passage 16 ([Figure 3](#fig3){ref-type="fig"}C). Finally, karyotype analyses and extensive investigation for genomic abnormalities using the Affymetrix CytoScan Array did not reveal chromosomal abnormalities in hESCs grown for 10 passages after nocodazole release ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D). Considered together, these results confirm that nocodazole treatment does not affect maintenance of pluripotency, does not induce differentiation, and does not compromise the genomic integrity of hESCs even after prolonged periods of time in culture.Figure 3Nocodazole Treatment Does Not Affect Pluripotency of hESCs(A) Brightfield images of H9 hESCs showing cell morphology after nocodazole release. Scale bars, 400 μm.(B) qRT-PCR analysis for pluripotency and differentiation markers in H9 hESCs through a time course of 24 hr after nocodazole release. Error bars represent ±SEM of two independent experiments.(C) qRT-PCR analysis for pluripotency and differentiation markers in H9 hESCs at passage 2, passage 3, and passage 16 after nocodazole treatment. Error bars represent ±SEM of triplicates in an independent experiment.(D) Representative flow cytometry analysis for OCT4 expression in H9 hESCs through a time course of 24 hr after nocodazole release.(E) Immunostaining analysis for the expression of pluripotency markers OCT4, NANOG, and SOX2 and differentiation markers BRACHYURY, EOMES, and SOX1 in DMSO- and nocodazole-treated H9 hESCs, two passages after nocodazole release. Scale bar, 200 μm.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Single-Cell RNA-Seq Confirms that Nocodazole Treatment Does Not Affect the Ability of Pluripotent Cells to Differentiate into Definitive Endoderm {#sec2.3}
-------------------------------------------------------------------------------------------------------------------------------------------------

To further characterize the effect of cell cycle synchronization, we decided to perform single-cell RNA-seq (scRNA-seq) on nocodazole and DMSO-treated cells before and after differentiation into endoderm. Accordingly, hPSC colonies were treated with DMSO or 100 ng/mL nocodazole for 16 hr and induced to differentiate into definitive endoderm for 3 days. Single cells were subsequently collected in either undifferentiated conditions or after 3 days of endoderm differentiation and then sorted onto 384 well plates for Smart-seq2 processing ([Figure 4](#fig4){ref-type="fig"}A). Principal component analysis (PCA) and t-Distributed Stochastic Neighbor Embedding (t-SNE) analysis showed a clear separation between pluripotent and endoderm cells while cell cycle synchronization has no effect on their transcriptional profile with the vast majority of these cells clustering together regardless of their synchronization condition ([Figures 4](#fig4){ref-type="fig"}B, [S3](#mmc1){ref-type="supplementary-material"}A, and S3B). Further PCAs show that the main difference between different cell populations (PC1, 40% of variance explained) is their differentiation stage (pluripotent versus endoderm) irrespective of whether they were treated with DMSO or nocodazole ([Figures 4](#fig4){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}A--S3C). Accordingly, key pluripotency genes, such as *POU5F1* (*OCT4*), *NANOG*, and *SOX2*, were only expressed in pluripotent cells, whereas endoderm genes, such as *SOX17*, *GATA6*, and *CER1*, were expressed in endoderm cells regardless of whether they were treated with DMSO or nocodazole ([Figure 4](#fig4){ref-type="fig"}C). These results confirm that nocodazole treatment is compatible with endoderm differentiation.Figure 4Single-Cell RNA-Seq Confirms that Nocodazole Treatment Does Not Affect the Ability of Pluripotent Cells to Differentiate into Definitive Endoderm(A) Schematic overview of experimental setup for performing single-cell RNA-seq analysis on pluripotent and endoderm cells following nocodazole treatment.(B) Plots showing two projections of a 3D t-SNE embedding. Dots represent individual cells. Cells were labeled based on their differentiation and synchronization status. Normalized log-expression values were used (DMSO = Green, nocodazole \[Noc\] = Purple, pluripotent \[Pluri\] = Circle, Endoderm = Triangle).(C) t-SNE plot showing the expression pattern of pluripotency (*POUF51*, *NANOG*, *SOX2*) and endoderm (*SOX17*, *GATA6*, *CER1*) genes in each cluster. Dots represent individual cells.(D) t-SNE plot showing the assignment of clusters identified by applying an SNN modularity optimization algorithm (see [Experimental Procedures](#sec4){ref-type="sec"}) in DMSO- and Noc-treated cells. Normalized log-expression values were used. Dots represent individual cells (DMSO = Circle, Noc = Triangle).(E) Heatmap showing the list of 50 differentially expressed genes obtained when merging the 10 genes with highest average log fold change in each cluster. Clusters 0, 3, and 4 represent undifferentiated cells and clusters 1 and 2 endoderm cells.(F) Scatterplot showing the log-average expression in cluster 1 versus cluster 2. Genes differentially expressed among cluster 1 and 2 are highlighted in light gray and red, with red representing genes with a log2FC ≥ 1. Genes that are not differentially expressed among these two groups are highlighted in green.(G) GO analyses of clusters 1 and 2 for the genes found in either cluster 1 (cluster 1 unique) or cluster 2 (cluster 2 unique), as well as for those genes that are not differentially expressed between these two groups (clusters 1 and 2).See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

However, it is important to mention that our analyses also revealed that the endoderm cells could be separated based on their synchronization status (DMSO versus nocodazole). Nonetheless, a more thorough investigation of this dataset showed that this separation is only evident by the third principal component (PC3), which explains less than 6% of the variance among the samples ([Figures 4](#fig4){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}A--S3C). To confirm this observation, we carried out clustering analysis using a shared nearest neighbor (SNN) modularity optimization algorithm (see [Experimental Procedures](#sec4){ref-type="sec"} section). This approach identified five individual clusters that for visualization purposes were presented in a t-SNE plot ([Figure 4](#fig4){ref-type="fig"}D). To determine the relationship among these clusters, the average expression for genes in each group was calculated and then used to carry out hierarchical clustering. The top 10 markers of each cluster were selected based on their differential expression when compared with other cells and presented in a heatmap ([Figure 4](#fig4){ref-type="fig"}E). This approach revealed that cells coming from the pluripotent cohort were classified in three different clusters. The segregation of clusters 0 and 3 seems to be explained only by biological heterogeneity of the pluripotent population ([Figure 4](#fig4){ref-type="fig"}E), whereas cluster 4, based on its proximity to the endoderm cohort, seems to represent a fraction of spontaneously differentiated cells that can be observed in conventional cultures of hPSCs ([Figure 4](#fig4){ref-type="fig"}E). Interestingly, these clusters include pluripotent cells both from DMSO and nocodazole conditions, confirming that nocodazole treatment does not affect the fundamental characteristics of pluripotent cells. Concerning endoderm cells, the hierarchical clustering suggests that these two groups are highly similar, although our SNN clustering approach did separate the endoderm cohort based on synchronization status (clusters 1 and 2 for DMSO and nocodazole respectively) ([Figure 4](#fig4){ref-type="fig"}E). To further confirm this observation, we carried out differential expression analysis for genes in clusters 1 and 2. Accordingly, we found that key endoderm marker genes, such as *SOX17*, *CXCR4*, and *GATA6*, are not among the differentially expressed between these two clusters, indicating that clusters 1 and 2 are similar in terms of differentiation status. However, this approach unveiled 33 genes significantly upregulated in cluster 1 versus cluster 2, and 38 genes significantly upregulated in cluster 2 versus cluster 1 ([Figure 4](#fig4){ref-type="fig"}F). The main difference originates from increased expression in genes involved in lipid and cholesterol metabolism (*ACAT2*, *FDFT1*, and *MVD* in cluster 1 and *APOE* in cluster 2, [Figure 4](#fig4){ref-type="fig"}F). Gene ontology (GO) analyses for the different clusters further confirmed that differences observed in DMSO- versus nocodazole-treated cells relate to metabolic processes, whereas processes common to both clusters involve tissue development ([Figure 4](#fig4){ref-type="fig"}G), thereby confirming the endodermal identity of these cells. The suggested change in metabolic activity could be explained by the lower density systematically observed in nocodazole-treated cells since they undergo at least one cell cycle less than their control. In addition, the loss in epithelial morphology occurring during synchronization in G2/M could also change metabolic requirement in cells treated with nocodazole. In summary, our analyses show that nocodazole synchronization has little effect on the differentiation capacity of the cells into endoderm while it does not affect the cellular identity of undifferentiated pluripotent stem cells or their capacity to differentiate into definitive endoderm.

hESCs Can Successfully Generate All Germ Layers and Functional Cell Types following Nocodazole Treatment {#sec2.4}
--------------------------------------------------------------------------------------------------------

We then decided to further characterize the differentiation capacity of nocodazole-treated hESCs using in-house and previously published protocols for directed differentiation into the three germ layers. H9 hESCs were treated with nocodazole for 16 hr and then grown in culture conditions inducing three mesoderm subtypes (lateral plate mesoderm \[LPM\], cardiac mesoderm \[CM\], and presomitic mesoderm \[PSM\]), as well as endoderm and ectoderm ([Figure 5](#fig5){ref-type="fig"}A) ([@bib7], [@bib19], [@bib32]). Immunostaining analysis for early mesoderm markers showed that nocodazole-treated cells differentiated efficiently as seen by the expression of BRACHYURY during LPM ([Figure 5](#fig5){ref-type="fig"}B) and PSM induction ([Figure 5](#fig5){ref-type="fig"}D) and the expression of EOMES during CM induction ([Figure 5](#fig5){ref-type="fig"}C). Moreover, expression of SOX17 during definitive endoderm differentiation was similar between DMSO- and nocodazole-treated cells ([Figure 5](#fig5){ref-type="fig"}E), as well as the expression of SOX1 during ectoderm differentiation ([Figure 5](#fig5){ref-type="fig"}F).Figure 5Nocodazole Treatment Does Not Affect the Capacity of hESCs to Differentiate into the Three Germ Layers(A) Schematic representation of the *in vitro* differentiation protocol to generate the three mesoderm subtypes lateral plate mesoderm (LPM), cardiac mesoderm (CM), and presomitic mesoderm (PSM) as well as endoderm and ectoderm. Treatment for the induction of the three mesoderm subtypes LPM, CM, and PSM is for 36 hr. Treatment for generation of endoderm is for 3 days and for ectoderm 6 days.(B--F) Immunostaining analysis for BRACHYURY expression during LPM induction (B), EOMES expression during CM induction (C), BRACHYURY expression during PSM induction (D), SOX17 expression in definitive endoderm (E), and SOX1 expression in ectoderm cells (F). Scale bars, 100 μm.

We further differentiated nocodazole-treated hESCs into functional cell types, such as smooth muscle cells (SMCs), cardiomyocytes, and chondrocytes arising from the mesoderm lineage and hepatocytes arising from the endoderm lineage. Gene expression analyses and functional assays showed a similar level of differentiation efficiency and functionality between DMSO- and nocodazole-treated hESCs. More precisely, SMC production was confirmed by monitoring the expression of *CNN1* and *TAGLN* ([Figure 6](#fig6){ref-type="fig"}A) while treatment with the cholinergic agent carbachol resulted in SMC contraction ([Figure 6](#fig6){ref-type="fig"}B). Analysis of cardiomyocytes generated from DMSO- and nocodazole-treated cells showed similar levels of expression of the cardiomyocyte markers *ACTN1* and *TNNT2* ([Figure 6](#fig6){ref-type="fig"}C), while their beating rate showed no differences ([Figure 6](#fig6){ref-type="fig"}D). Similarly, chondrocytes generated from DMSO- and nocodazole-treated cells showed no differences in expression of *ACAN* and *COL2A* ([Figure 6](#fig6){ref-type="fig"}E), while functionality was assessed by probing proteoglycan release using Alcian blue staining. Our results showed similar levels of Alcian blue staining and release in DMSO- versus nocodazole-treated chondrocytes ([Figure 6](#fig6){ref-type="fig"}F). Concerning endoderm differentiation, DMSO- and nocodazole-treated cells showed high expression of the hepatocyte markers *ALB* and *A1AT* ([Figure 6](#fig6){ref-type="fig"}G) and displayed comparable CYP3A4 activity ([Figure 6](#fig6){ref-type="fig"}H). In summary, these results show that nocodazole does not affect the capacity of hESCs to differentiate into the three primary germ layers as well as their capacity to produce functional cell types, such as SMCs, cardiomyocytes, chondrocytes, and hepatocytes.Figure 6hESCs Can Generate Functional Cell Types following Nocodazole Treatment(A) qRT-PCR analysis for SMC markers in DMSO and nocodazole-treated cells. Error bars represent ±SEM of three independent experiments. Ordinary one-way ANOVA test followed by Sidak\'s test for comparison of DMSO versus nocodazole-treated cells was performed. (ns, not significant).(B) Contractility of SMCs was induced by carbachol. Panels show cells contracting within 10 min of carbachol treatment. Graph shows % contraction of 20 cells in DMSO control and nocodazole-treated cells. Error bars represent ±SEM.(C) qRT-PCR analysis for cardiomyocyte markers in DMSO and nocodazole-treated cells. Error bars represent ±SEM of three independent experiments. Ordinary one-way ANOVA test followed by Sidak\'s test for comparison of DMSO versus nocodazole-treated cells was performed (ns, not significant).(D) Graph showing beating rate of cardiomyocytes generated form DMSO and nocodazole-treated cells. Error bars represent ±SEM (n = 4).(E) qRT-PCR analysis for chondrocyte markers in DMSO- and nocodazole-treated cells. Error bars represent ±SEM of two independent experiments.(F) Alcian blue staining of chondrocytes shows Alcian blue absorption and release of DMSO control and nocodazole-treated cells. Error bars represent ±SEM of triplicates in an independent experiment.(G) qRT-PCR analysis for hepatocyte markers in DMSO and nocodazole-treated cells. Error bars represent ±SEM of triplicates in an independent experiment.(H) Hepatocytes generated from DMSO and nocodazole-treated cells display cytochrome P450 3A4 activity, as assessed by the enzymatic release of free luciferin by cytochrome P450 from an inactive luciferin precursor. Error bars represent ±SEM of triplicates in an independent experiment.

Nocodazole Synchronization Method Works with a Diversity of Human Induced PSCs {#sec2.5}
------------------------------------------------------------------------------

To validate that nocodazole synchronization can be applied to a variety of cell lines, we used three additional human induced PSC (hiPSC) lines: a wild-type line (FSPS13B) and two lines derived from patients with cystic fibrosis (CF04 and CF05). These three lines were successfully enriched in the G2/M phase upon nocodazole treatment ([Figures 7](#fig7){ref-type="fig"}A--7C), while near homogeneous enrichment in G1 phase (70%) was obtained 4 hr and in S phase (80%) 12 hr after release ([Figures 7](#fig7){ref-type="fig"}A--7C). Asynchronous cell cycle profile similar to the DMSO-treated cells was recovered 24 hr after nocodazole release, confirming the results obtained in hESCs ([Figures 7](#fig7){ref-type="fig"}A--7C). We then determined the ability of synchronized hiPSC lines to generate mesoderm subtypes. Immunostaining analysis showed that HAND1 was expressed during LPM induction, EOMES during CM induction, and BRACHYURY during PSM induction ([Figures 7](#fig7){ref-type="fig"}D--7F). Moreover, karyotypic analyses of three hiPSC lines FSPS13B, CF03, and CF05 7, 16 and 9 passages after nocodazole release respectively, confirmed that the cells maintain a normal karyotype prior to and after treatment with nocodazole ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4C). In summary, synchronization of cell cycle by nocodazole works efficiently in a diversity of hPSC lines and does not affect their basic characteristics, suggesting that this approach could be used with a broad diversity of cell lines.Figure 7Human iPSCs Can Be Synchronized with Nocodazole while Maintaining Their Capacity of Differentiation(A--C) Cell cycle profile of hiPSCs lines FSPS13B (A), CF04 (B), and CF05 (C) following treatment and release from nocodazole.(D--F) Immunostaining analysis for the expression of early mesoderm markers HAND1 (during LPM induction, D), EOMES (during CM induction, E), and BRACHYURY (during PSM induction, F) in DMSO- and nocodazole-treated cells after 36 hr of differentiation. Scale bar, 100 μm.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

The limited tools available to study cell cycle dynamics in hPSCs prompted us to characterize and optimize the use of small molecule cell cycle inhibitors to synchronize and enrich hPSCs in the different phases of the cell cycle. A number of reports have shown the use of small molecules, such as nocodazole, aphidicolin, and hydroxyurea, to synchronize hPSCs ([@bib2], [@bib9], [@bib10], [@bib11], [@bib20], [@bib35]); however, their effect on pluripotency, genetic stability, and capacity of differentiation has not been extensively investigated. In this study, we showed synchronization in S phase using aphidicolin (85% of the cells) and hydroxyurea (70% of the cells) with higher efficiencies than previously reported ([@bib10]). Moreover, we reported efficient synchronization by nocodazole with more than 90% of cells enriched in the G2/M phase, while G1 inhibitors were systematically inefficient or toxic to the cells. This last observation suggests that blocking hESCs in this phase of the cell cycle is particularly challenging potentially due its critical function in cell fate decisions ([@bib22], [@bib28]).

Following small molecule treatment and removal, the S phase inhibitors failed to enrich the cells in G2/M and G1 phase, with most of the cells remaining in S phase several hours after release from the inhibitors. This could be due to the inhibitors causing permanent arrest of the cells. Furthermore, S phase lasts more than 6 hr in hPSCs and thus synchronization is unlikely to be homogeneous. The G2/M inhibitor nocodazole proved to be the most successful inhibitor not only in blocking cell cycle progression but also in producing populations of hPSCs synchronous for cell cycle progression after release without causing significant cell death. We also showed that the expression of cyclin D proteins elicit the expected periodicity in the different cell cycle phases, suggesting that nocodazole treatment does not perturb the cell cycle machinery. Of note, synchronization was maintained in part for one cell cycle after release (70% cells in G1 and 80% cells in S phase) suggesting that our approach could be useful to study events happening in each of these cell cycle phases. However, investigating mechanisms occurring in a very precise and time-limited phase of the cell cycle such as early G1 or G1/S transition, might require additional sorting strategy.

The efficiency of nocodazole synchronization could be explained by its effect on microtubule polymerization during mitosis, which represents a very short phase of the cell cycle in hPSCs. Thus, blocking cell cycle progression in this phase of the cell cycle would result in a homogeneous and synchronized population. Further characterization showed that nocodazole treatment did not affect pluripotency in agreement with previous reports ([@bib11], [@bib35]). Of note, a previous report stated that expression of pluripotency markers is reduced irreversibly upon nocodazole treatment. Nonetheless, this report did not use the same protocol of synchronization and successful enrichment in the G2/M phase upon nocodazole treatment was not observed (approximately 53%). Thus, different dose/time and culture conditions are likely to affect the efficacy of nocodazole treatment and its effect on pluripotency ([@bib15]).

We further used our approach to perform single-cell RNA-seq analysis of synchronous and asynchronous cells during the process of endoderm differentiation. These analyses showed that nocodazole-treated hPSCs efficiently differentiated into a near homogeneous population of endoderm cells after 72 hr. Nonetheless, nocodazole treatment increased the heterogeneity of the endoderm population probably by decreasing the speed by which some cells can reach the endoderm state. This delay could be explained by the lower density systematically observed in nocodazole-treated cells that undergo at least one cell cycle less than their DMSO-treated counterpart. In addition, the loss in epithelial morphology observed during nocodazole treatment could decrease the speed by which nocodazole-treated cells can differentiate. Finally, the start of the differentiation and/or the exit from pluripotency could be delayed by the inhibition of cell cycle progression as suggested by others ([@bib10]).

Importantly, this increase in heterogeneity had little or no effect on the capacity of differentiation of hPSCs or on the production of terminally differentiated cell types. Indeed, nocodazole-treated cells were able to efficiently generate all the germ layers and some of their derivatives, including SMCs, cardiomyocytes, chondrocytes, and hepatocytes. These findings were validated on three independent hiPSC lines, thereby demonstrating the robustness of our method for synchronizing cell cycle in pluripotent stem cells. Thus, cell synchronization of hPSCs by nocodazole does not affect their fundamental properties.

To conclude, the approach described in our study will enable new investigations, especially detailed molecular analyses of the interplays between cell cycle machinery, transcription factors, and epigenetic modifiers during cell cycle progression in pluripotent stem cells and during differentiation.

Experimental Procedures {#sec4}
=======================

hPSC Culture and Differentiation {#sec4.1}
--------------------------------

H9 hESCs (WiCell, Madison, WI, USA) and the hiPSC lines FSPS13B, CF03, CF04, and CF05 were plated on vitronectin-coated plates (10 μg/mL, Stem Cell Technologies) and cultured in E6 media supplemented with 2 ng/mL transforming growth factor β (R&D) and 25 ng/mL fibroblast growth factor 2 (Dr. Marko Hyvönen, Cambridge University) making complete E8 media. Cells were maintained by weekly passaging using 0.5 mM EDTA (Thermo Fisher Scientific). The cells were differentiated into the three germ layers and functional cell types as previously described ([@bib7], [@bib19]) and as described in the [Supplemental Information](#app2){ref-type="sec"}.

Synchronization and Differentiation of Cells Using Nocodazole {#sec4.2}
-------------------------------------------------------------

For synchronization into the G2/M phase of the cell cycle, cells were treated with 100 ng/mL of nocodazole (Sigma-Aldrich) for 16 hr. For enrichment of the cells into the different cell cycle phases, cells were washed twice with E8 media and cultured in maintenance media for 2, 4, 6, 12, and 24 hr. For differentiation following nocodazole treatment, cells were plated and treated with nocodazole the next day (for mesoderm differentiation) or 2--3 days after plating (for endoderm and ectoderm differentiation). Following two washes with E8 media, cells were induced to differentiate using the protocols described in the [Supplemental Information](#app2){ref-type="sec"}.

Cell Cycle Profile Analysis {#sec4.3}
---------------------------

Cell cycle profile analysis was performed using the Click-iT EdU Pacific Blue Flow Cytometry Assay Kit (Thermo Fisher Scientific) according to the manufacturer\'s instructions. In summary, cultured cells were incubated at 37°C with 10 μM EdU (5-ethynyl-2′-deoxyuridine) for 1 hr and harvested using cell dissociation buffer (Gibco). After three washes with PBS/1% BSA, cells were fixed with 4% paraformaldehyde for 15 min at room temperature and washed three more times with PBS/1% BSA. Cells were then permeabilized for 15 min with saponin-based permeabilization/wash buffer and incubated with the Click-iT reaction cocktail for 30 min protected from light. Cells were washed once with saponin-based permeabilization/wash buffer and stained for DNA content using the FxCycle Far Red dye (Invitrogen). Cells were analyzed on the Cyan ADP flow cytometer and FlowJo software.

Single-Cell RNA-Seq {#sec4.4}
-------------------

hiPSCs (FSPS13B) were either treated with DMSO or nocodazole 16 hr before the start of differentiation. Cell sorting and library preparation was carried out by the sequencing core facility at the Sanger Institute. Briefly, single hPSCs were isolated into 384-well plates and libraries were prepared for 120 cells per condition using the Smart-seq2 protocol. A constant amount of spike-in RNA from the External RNA Controls Consortium was also added to the lysis buffer prior to sorting. Transcript expression quantification was performed with "Salmon" ([@bib21]) and collapsed to gene level using "Scater" ([@bib18]); Quality control metrics calculations, normalization, and PCA analyses were carried out using "Scater" and "Seurat" ([@bib5]). Low-quality cells were removed based on total number of counts/cell, proportion of counts in mitochondrial genes, or spike-in transcripts. Normalization was performed in Seurat by applying the default "LogNormalize" method that normalizes the gene expression measurements for each cell by the total expression, multiplies this by a scale factor and log-transforms the result. Highly variable genes were selected, the number of detected molecules was regressed out, and scaled *Z*-scored residuals were employed for downstream analysis. An SNN modularity optimization-based algorithm ([@bib34]) was used to identify the clusters presented in [Figure 4](#fig4){ref-type="fig"}D. Markers for every cluster were identified by calculating differential expression of each cluster compared with all remaining cells (Wilcoxon rank-sum test). The 10 genes with highest average log fold change were selected for each cluster as top markers and their log-average expression was used as an input for hierarchical clustering ([Figure 4](#fig4){ref-type="fig"}E). Enrichment of GO biological processes was obtained with the R package g:Profiler ([@bib26]). Due to the hierarchical structure of GO terms, the categories were grouped together when sharing enriched parents by applying the "moderate" option, which selects the most significant category from each of such groups. Correction for multiple testing was performed with the false discovery rate. RNA-seq data have been deposited in the ArrayExpress database at EMBL-EBI ([www.ebi.ac.uk/arrayexpress](http://www.ebi.ac.uk/arrayexpress){#intref0010}) under accession number E-MTAB-7008.

Statistical Analysis {#sec4.5}
--------------------

Statistical analyses were performed using GraphPad Prism 7 software. The type of statistical analysis performed in each experiment and the number of replicates used are described in the figure legends. For comparison of multiple groups, one-way ANOVA was performed. Significance in each analysis is represented by ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001, ns = not significant.
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